The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell
August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnson Medical Devices Companies, announced today that data from 16 company sponsored studies will be presented at Heart Rhythm 2021, the Heart Rhythm Society (HRS) annual meeting. The data presented reflects Biosense Webster’s continued innovation and commitment to advancing science in the field of electrophysiology with the goal of improving patient outcomes.
Presentation topics included new data on novel technologies spanning Carto mapping technology, diagnostic catheters, therapeutic catheters, and the role of digital technologies in advancing cardiac arrhythmia treatment. Additionally, two abstracts will be presented highlighting real-world data on atrial fibrillation treatment outcomes.
As part of the Biosense Webster booth, a variety of interactive experiences will be available including hands-on demonstrations of the new Octaray high density mapping catheter with TRUEref Technology, CartoNet cloud-based software solution, and NuVision Ultrasound Catheter with imaging support from GE Healthcare Vivid Ultra Edition ultrasound systems.
For more information about Biosense Webster’s presence at Heart Rhythm 2021: www.BiosenseWebsterHRS.com
For more information: www.biosensewebster.com